Insmed has announced that it will discontinue the development program for brensocatib in a chronic inflammatory skin condition after the drug failed to meet its primary and secondary efficacy endpoints in a phase 2b trial.
In the CEDAR study, Insmed tested 10 mg and 40 mg oral doses of brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS). At week 16, the reduction from baseline in total abscess and inflammatory nodule (AN) count was 45.5% and 40.3% respectively, compared to 57.1% with a placebo.
Brensocatib is a dipeptidyl peptidase 1 (DPP1) inhibitor that targets neutrophilic inflammation by activating neutrophil serine proteases. It was originally approved by the FDA in August 2025 as Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis (NCFB).
It has FDA approval for treating non-cystic fibrosis bronchiectasis (NCFB) at doses of 10 mg and 25 mg. The 40 mg dose in the CEDAR clinical trial is the highest dose Insmed has tested to date and had no new safety indications.